(Q43256421)

17 November 2017

title

Homotaurine: a failed drug for Alzheimer's disease and now a nutraceutical for memory protection (English)

1 reference

17 November 2017

0 references

1 reference

Michael T Swanoski

1

1 reference

17 November 2017

publication date

1 November 2009

1 reference

American Journal of Health-System Pharmacy

17 November 2017

published in

1 reference

17 November 2017

volume

66

1 reference

17 November 2017

issue

21

1 reference

17 November 2017

page(s)

1950-1953

1 reference

Alzheimer Disease in the US Population

17 November 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080576

Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080576

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080576

Emerging prospects for the disease-modifying treatment of Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080576

Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080576

The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080576

Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080576

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080576

Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080576

Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080576

A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080576

Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080576

New Canadian natural health product regulations: a qualitative study of how CAM practitioners perceive they will be impacted

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080576

Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080576

31 March 2020

Identifiers

DOI

10.2146/AJHP080576

1 reference

17 November 2017

1 reference